Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Perakakis N, Bornstein SR, Birkenfeld AL, Linkermann A, Demir M, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Kolkhof P, Lawatscheck R, Scott C, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Perakakis N, et al. Among authors: rossing p. Diabetes Obes Metab. 2024 Jan;26(1):191-200. doi: 10.1111/dom.15305. Epub 2023 Oct 10. Diabetes Obes Metab. 2024. PMID: 37814928
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL. Ruilope LM, et al. Among authors: rossing p. Am J Nephrol. 2014;40(6):572-81. doi: 10.1159/000371497. Epub 2015 Jan 10. Am J Nephrol. 2014. PMID: 25591469 Clinical Trial.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Bakris GL, et al. Among authors: rossing p. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. JAMA. 2015. PMID: 26325557 Clinical Trial.
The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, Rossing P. von Scholten BJ, et al. Among authors: rossing p. Diabetes Obes Metab. 2017 Feb;19(2):239-247. doi: 10.1111/dom.12808. Epub 2016 Nov 21. Diabetes Obes Metab. 2017. PMID: 27753201 Clinical Trial.
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, E Klein B, Klein R, Ooi TC, Rossing P, Sattar N, Stehouwer CD, Colhoun HM; REMOVAL Trial Team. Petrie JR, et al. Among authors: rossing p. Diabetes Obes Metab. 2017 Apr;19(4):509-516. doi: 10.1111/dom.12840. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27935183 Free PMC article. Clinical Trial.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P. von Scholten BJ, et al. Among authors: rossing p. Diabetes Obes Metab. 2017 Jun;19(6):901-905. doi: 10.1111/dom.12884. Epub 2017 Mar 2. Diabetes Obes Metab. 2017. PMID: 28105731 Clinical Trial.
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.
Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P. Tofte N, et al. Among authors: rossing p. Diabet Med. 2018 Oct;35(10):1375-1382. doi: 10.1111/dme.13669. Epub 2018 Jun 6. Diabet Med. 2018. PMID: 29781558 Free article. Clinical Trial.
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. de Zeeuw D, et al. Among authors: rossing p. Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6. Lancet Diabetes Endocrinol. 2018. PMID: 30413396 Clinical Trial.
789 results